secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2022-05-23T23:59:59+00:00
Accession:  0001140361-22-020177
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed appoints Drayton Wise as Chief Commercial Officer; $500k salary, $2.1M equity award
--------------------------------------------------------------------------------

- Drayton Wise appointed CCO effective May 23, 2022; previously SVP Head of US & GM of ARIKAYCE.
- Annual base salary of $500,000; target bonus 40% of base; RSU and option award valued at $2.1M.
- RSUs vest 25% per year over four years; options vest 25% on first anniversary then 12.5% semiannually.
- Wise to lead all global commercial functions and join Executive Committee; CEO cites brensocatib launch prep.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036122020177/0001140361-22-020177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036122020177/brhc10037965_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-020177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer